Gyrodyne, LLC — Form 10-Q Summary
Reporting period: Quarter ended September 30, 2022; financial activity discussed primarily for the nine months ended that date. Gyrodyne is a real-estate company pursuing entitlements and asset sales before liquidation. Its statements use the liquidation basis of accounting, so conventional income-statement and cash-flow-statement presentations are not provided.
Financial position and operating metrics
| Metric | September 30, 2022 | December 31, 2021 |
|---|---|---|
| Total assets | $47.12 million | $48.28 million |
| Real estate held for sale | $42.55 million | $42.55 million |
| Cash and cash equivalents | $4.38 million | $5.67 million |
| Loans payable | $9.83 million | $10.03 million |
| Total liabilities | $24.25 million | $25.26 million |
| Net assets in liquidation | $22.87 million | $23.03 million |
| Estimated liquidation value per share | $15.42 | $15.53 |
- For the nine months, rent and tenant reimbursements were $2.25 million, property operating costs were $1.34 million, and reported net operating income was $914,279. Corporate expenditures were $1.60 million; interest expense was $318,105; property capital expenditures excluding entitlement costs were $106,679.
- There is no clear consolidated revenue, net income, or conventional operating cash flow figure in the filing’s liquidation-basis statements. The company reported $194,804 of entitlement costs net of vendor deferrals during the period.
- Debt consists of two Flowerfield loans with fixed 3.85% rates and a Cortlandt Manor mortgage initially bearing 3.75%. The company reported compliance with loan covenants. Scheduled debt maturities are concentrated in 2027 and thereafter.
Changes versus the prior comparable balance-sheet date
Net assets declined $158,054, or approximately $0.11 per share, from December 31, 2021. The real-estate liquidation valuation was unchanged. The decline reflected remeasurement of estimated liquidation and operating costs net of receipts, including approximately $500,000 of anticipated legal costs to defend the Flowerfield proceeding, other added costs net of savings, and approximately $488,000 of additional estimated revenue. Cash decreased by approximately $1.29 million.
Outlook, risks, and notable items
- Liquidation plan: Management estimates net assets of $22.87 million, or $15.42 per share, based on 1,482,680 shares outstanding. It estimates completion of property sales and liquidation by year-end 2024, but cautions that actual proceeds, timing, and distributions may differ materially. The estimate is not a guaranteed distribution.
- Entitlements and sales: Smithtown granted preliminary approval in March 2022 to subdivide Flowerfield into eight lots. The company anticipates final subdivision approvals for Flowerfield and Cortlandt Manor in 2023. It estimates approximately $1.09 million of additional entitlement costs through the current liquidation timeline.
- Litigation: Head of the Harbor and other parties filed an Article 78 proceeding seeking to annul the Flowerfield environmental findings and preliminary subdivision approval. Gyrodyne and Smithtown are defending the approvals; the proceeding could take two years or more and delay transactions. Management’s estimated liquidation costs include legal expenses related to the case.
- Market and tenant risks: Management cites inflation, rising interest rates, possible recession, real-estate valuation pressure, COVID-19 effects, approval delays, labor shortages, environmental concerns, community opposition, and tenant operating difficulties. Three largest tenants accounted for approximately 23%, 21%, and 9% of nine-month rental income; tenants unaffiliated with major hospitals represented approximately 41% of projected 2022 rental revenue.
- Other obligations: Estimated liquidation and operating costs net of receipts were $11.52 million. The estimated retention-bonus liability was $3.28 million; no plan payments were made during the nine months. Deferred director compensation and vendor payments also affect future cash needs.
- Controls: Management concluded disclosure controls were not effective because of a material weakness in controls over estimated real-estate values. Remediation efforts are underway; the filing states the weakness did not result in a material misstatement.
Investor verification priorities
- Track court developments in the Article 78 proceeding and whether Flowerfield’s preliminary approvals remain in effect.
- Verify progress toward final approvals, site-plan approvals, property-sale agreements, and the year-end 2024 liquidation target.
- Assess the assumptions behind the $42.55 million real-estate valuation and the $15.42-per-share estimated liquidation value, including sale prices, costs, and timing.
- Monitor cash usage, debt repayment and maturity requirements, deferred vendor obligations, and whether liquidity remains adequate through liquidation.
- Follow remediation and testing of the material weakness in real-estate valuation controls.